Aug 27 (Reuters) – AstraZeneca said on Thursday its asthma drug, Tezspire, developed with Amgen, met its main and secondary goals in a late-stage trial for treating eosinophilic esophagitis, a chronic inflammatory disorder of the esophagus.
(Reporting by Raechel Thankam Job in Bengaluru; Editing by Mrigank Dhaniwala)
Comments